FDA Grants Priority Review to Afatinib for NSCLC With Rare EGFR Mutations

October 10, 2017 – The FDA has granted a priority review to a supplemental new drug application (sNDA) for afatinib for the frontline treatment of patients with metastatic non–small cell lung cancer (NSCLC) whose tumors harbor EGFR exon 21 (L861Q), G719X, or S768I substitution mutations. Uncommon mutations such as these represent less than 10% of the EGFR mutations found in NSCLC patients, but are associated with poor prognosis and survival, Boehringer Ingelheim … (leggi tutto)